• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.500 +0.400 (+9.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,967,739
Open 4.100
Bid (Size) 4.410 (100)
Ask (Size) 4.570 (200)
Prev. Close 4.100
Today's Range 4.070 - 4.570
52wk Range 3.430 - 11.24
Shares Outstanding 77,740,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From Verastem Oncology
Via Business Wire
News headline image
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
June 23, 2026
From Verastem Oncology
Via Business Wire

Performance

YTD
-37.8%
-37.8%
1 Month
+24.3%
+24.3%
3 Month
-17.9%
-17.9%
6 Month
-37.8%
-37.8%
1 Year
-6.2%
-6.2%

More News

Read More
News headline image
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
June 17, 2026
From Verastem Oncology
Via Business Wire
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
May 07, 2026
Via Chartmill
Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch ↗
March 04, 2026
Via Chartmill
News headline image
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
June 16, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
June 15, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
June 03, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Jefferies Healthcare Conference
May 27, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
May 12, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Q1 Earnings Call Highlights ↗
May 09, 2026
Via MarketBeat
Topics Earnings
News headline image
Verastem (VSTM) Q1 2026 Earnings Transcript ↗
May 08, 2026
Via The Motley Fool
News headline image
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 08, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 07, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
April 30, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
April 10, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
March 17, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
March 17, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗
March 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗
March 04, 2026
Via Stocktwits
Topics Earnings
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
March 04, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
February 18, 2026
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 4.500
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 07/02/26 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 349.83M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 350M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap